BEAT News 8.60 Cardionet (BEAT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cardionet (BEAT) 8.60 $BEAT

11.0% Return Seen to Date on SmarTrend CardioNet Call (BEAT)
Comtex SmarTrend(R) - Tue Apr 08, 11:18AM CDT
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 2 months, CardioNet has returned 11.00% as of today's recent price of $9.79.

CardioNet Shares Up 17.8% Since SmarTrend's Buy Recommendation (BEAT)
Comtex SmarTrend(R) - Tue Apr 01, 9:59AM CDT
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 2 months, CardioNet has returned 17.80% as of today's recent price of $10.39.

BioTelemetry, Inc. Announces the Acquisition of the Cardiac Patient Services Business of Biomedical Systems, Corp.
GlobeNewswire - Thu Mar 20, 7:14AM CDT
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced that it has entered into a definitive agreement to acquire the cardiac patient services business of Biomedical Systems, Corp. ("BMS" for aggregate consideration of $8.65 million at closing. Post integration, the acquisition is expected to generate $8.0 to $9.0 million in revenue and $2.5 to $3.0 million in EBITDA on an annualized basis. The transaction is expected to close in early April.

CardioNet Up 15.5% Since SmarTrend Uptrend Call (BEAT)
Comtex SmarTrend(R) - Mon Mar 17, 5:33PM CDT
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 1 month, CardioNet has returned 15.53% as of today's recent price of $10.19.

CardioNet Earnings In Retrospect: Up 4.9% in the Last 19 Days (BEAT)
Comtex SmarTrend(R) - Mon Mar 17, 7:10AM CDT
Two weeks ago on February 26th, 2014 CardioNet (NASDAQ:BEAT) reported earnings and analysts, on average, expected a loss of $0.02 on sales of $32.3 million. CardioNet actually reported earnings of $0.05 per share on sales of $33.1 million, beating EPS estimates by $0.07 and beating revenue estimates by $0.8 million. Since the company's report, shares of CardioNet have risen from $9.85 to $10.33, representing a gain of 4.9% in the past 19 days.

BioTelemetry (BEAT): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:33AM CDT
BioTelemetry belongs to the Medical Services industry, will be a decent pick, as the company witnessed solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.

CardioNet Earnings Review: 12 Days after Announcement Shares Up 10.7% (BEAT)
Comtex SmarTrend(R) - Mon Mar 10, 7:53AM CDT
A week ago on February 26th, 2014 CardioNet (NASDAQ:BEAT) reported earnings and analysts, on average, expected a loss of $0.02 on sales of $32.3 million. The company actually reported EPS of $0.05 on sales of $33.1 million, beating EPS estimates by $0.07 and beating revenue estimates by $0.8 million. Since the company's report, shares of CardioNet have risen from $9.85 to $10.90, representing a gain of 10.7% in the past 12 days.

Why BioTelemetry (BEAT) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:00AM CST
BioTelemetry has decent short-term momentum and solid activity on the earnings estimate revision front

25.4% Return Seen to Date on SmarTrend CardioNet Call (BEAT)
Comtex SmarTrend(R) - Mon Mar 03, 9:49AM CST
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 4 weeks, CardioNet has returned 25.40% as of today's recent price of $11.06.

BioTelemetry, Inc. (BEAT) Surges: Stock Moves 13.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:21AM CST
BioTelemetry, Inc. (BEAT) was a big mover last session, as the company saw its shares rise by roughly 14% on the day.

Why BioTelemetry (BEAT) Is Spiking Today
at The Street - Thu Feb 27, 12:52PM CST
BioTelemetry (BEAT) rises after the company, which provides products and services to healthcare professionals to help diagnose and monitor patients, reported fourth-quarter earnings that surpassed analysts' expectations. BioTelemetry reported fourth...

Surging Rank, Surging Stock: Why BioTelemetry (BEAT) Is a Winner? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:38AM CST
BioTelemetry (BEAT) sees rank surges as well as price appreciation over the past few weeks, gaining over 36% in the past month.

BioTelemetry, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the fourth quarter and full year-ended December 31, 2013.

Omnicare Earnings Rise but Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 11:30AM CST
For full year 2013, OCR's adjusted net earnings per share grew 9.9% to $3.43 from $3.12 a year ago, also lagging the Zacks Consensus Estimate of $3.61.

BioTelemetry (BEAT) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:51AM CST
BioTelemetry (BEAT) Shares March Higher, Can It Continue?

Why Quintiles Transnational (Q) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:30AM CST
Quintiles Transnational has seen its Zacks Rank move up from Buy to Strong Buy over the past four weeks

Healthways Sees 4Q Loss on Lower Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 1:07PM CST
Healthways failed to meet its own revenue expectations of 171 to $181 million for the fourth quarter and $665-$675 million for the full year
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 147

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 59

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 114

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 19

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 139

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading

Top 5 Most Recently Viewed Articles

Trinseo Announces New Dividend Amid Strategic Changes Ahead

Updated Category News Views 225

Trinseo Approves Dividend for Shareholders Trinseo (NYSE: TSE), a prominent provider of specialty material solutions, has recently announced a quarterly dividend approved by its Board of Directors. The dividend declared stands at $0.01 per share, set to be distributed on a future date, offering a slight financial incentive for shareholders. To be eligible, shareholders...

Continue Reading
2026 Mighty 25: Celebrating Military Community Leaders

Updated Category News Views 26

A Spotlight on Unsung Heroes Tampa, Florida, just got a little mightier as We Are The Mighty rolls out the red carpet for the 2026 Mighty 25. This annual roll call, backed by CareSource Military & Veterans™, shines a light on veterans, military spouses, creators, entrepreneurs, and change agents defying the status quo. They are redefining impact across the military...

Continue Reading
Rubrik Inc Soars as Earnings Beat Expectations

Updated Category News Views 238

Rubrik Inc's Recent Stock Surge Rubrik, Inc. (NYSE: RBRK) has recently captured the attention of the market as its shares have risen over 20% following an impressive report of fourth-quarter earnings. The company exceeded expectations in both profitability and revenue, which undoubtedly prompted a wave of investor optimism. Financial Performance Highlights For the latest...

Continue Reading
Sanofi’s Amlitelimab Achieves Key Study Goals for Eczema Treatment

Updated Category News Views 284

Sanofi’s Amlitelimab Revolutionizes Atopic Dermatitis Treatment In an exciting development for patients suffering from atopic dermatitis, Sanofi's amlitelimab has met all primary and key secondary endpoints in the pivotal COAST 1 phase 3 study, targeting both adults and adolescents. This innovative medication demonstrated meaningful efficacy in terms of skin clearance...

Continue Reading
Alphamin Resources Corp: Board Changes and Future Outlook

Updated Category News Views 168

Leadership Changes at Alphamin Resources Corp Alphamin Resources Corp., a prominent player in the mining sector, recently shared significant news regarding its board of directors. The company announced the resignation of Mr. Rudolf Pretorius as a director. This change marks a pivotal moment in the company’s leadership structure, as Mr. Pretorius had been with the board...

Continue Reading